DMAA

Drugs Made In America Acquisition Corp.
CAPPED RATING

Drugs Made In America Acquisition Corp. operates as a blank check company. The Company aims to acquire one and more businesses and assets, via a merger, capital stock exchange, asset acquisition, stock purchase, and reorganization.

Drugs Made In America Acquisition Corp. (DMAA) is rated D+ (1.7/5) on Deltasharpe Prism, scored against Financial Services sector peers. Its strongest pillar is Momentum (B-); its weakest is Value (F). The rating has held at D+ for 7 weeks.

Quantitative Factor Evaluation • Updated

Overall Rating
1.7 / 5.0
D+
Value
F
Factor Score 0.1 / 5.0
Growth
D+
Factor Score 1.6 / 5.0
Profitability
D
Factor Score 1.5 / 5.0
Momentum
B-
Factor Score 3.0 / 5.0
Revisions
C+
Factor Score 2.5 / 5.0

Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms

Ratings of B- and above are for members.

Register free to see every rating — your first 2 weeks of Premium are on us.

Register — 2 weeks free

Underlying Financial Metrics

P/E Ratio 60.6
EV / EBITDA N/A
Rev Growth YoY N/A
Gross Margin 0.0%
Price Return 3M 1.8%
Price Return 12M 5.7%
Catalyst Signal 0.00
Market Cap $264.6M
TTM Revenue N/A
Price / Sales N/A
ROE N/A

Historical Factor Score Progression

Held D+ for 7 weeks
Date Value Growth Profitability Momentum Revisions Overall
2026-11-11 F (0.1) D+ (1.6) D (1.5) B- (3.0) C+ (2.5) D+ (1.7)
2026-11-04 F (0.1) D+ (1.5) D (1.5) B- (3.0) C+ (2.5) D+ (1.7)
2026-10-28 F (0.1) D (1.5) D (1.5) B- (2.9) C+ (2.5) D+ (1.7)
2026-10-21 F (0.1) D (1.5) D (1.5) C+ (2.8) C+ (2.5) D+ (1.7)
2026-10-14 F (0.1) D (1.4) D (1.5) C+ (2.7) C+ (2.5) D+ (1.6)
Page 1 of 4